Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the Fib-4 score may predict early hematological adverse effects in HCV-infected patients on IFN-based triple therapy.
|
30657408 |
2019 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ-Hepatic Fibrosis and Cancer.
|
30998425 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants of rs2111485 and rs1990760 at <i>IFIH1</i> may be associated with spontaneous HCV clearance in Chinese Han population, but have no effect on HCV clearance induced by IFN-<i>α</i>.
|
31539314 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In uremic subjects, polymorphisms within the IFN-λ chromosomal region associate with spontaneous HCV clearance, similarly like in the non-uremic population.
|
30027841 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Brazilian Public Health Service provides freely αPEG-IFN to treat patients infected with HCV.
|
30243981 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
By demonstrating that IFN-λ variation leaves a large footprint on the viral proteome, we provide evidence of pervasive viral adaptation to innate immune pressure during chronic HCV infection.
|
31478832 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations present an apparent conundrum-when and how does a presumably good IFN, with anti-HCV activity, interfere with the ability to clear HCV?
|
31241411 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in the IFN-λ region have also been associated with hepatic inflammation and fibrosis from various etiologies, however, alleles that are linked with improved HCV clearance associates with worse inflammation and fibrosis.
|
31161939 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment-emergent depression is a common complication in patients with chronic hepatitis C virus (HCV) infection undergoing antiviral combination therapy with IFN-α and ribavirin.
|
31332697 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An interferon λ4 gene (IFNL4) knockout allele (rs368234815; TT) is associated with spontaneous and IFN-α-dependent cure of hepatitis C virus infection.
|
30289470 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these findings, ribavirin-induced anti-RR autoantibody seems to be associated with a more frequent nonresponse to IFN-<i>α</i>/ribavirin therapy with a significant higher HCV viral load.
|
31081724 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
DAA therapy causes far fewer adverse reactions compared with IFN therapy and has been reported to be highly effective in treating HCV infection in hemodialysis patients.
|
30041215 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to determine the association of rs2430561 and rs4073 polymorphisms in the Interferon gamma (IFN-ɤ) and Interleukin 8 (IL-8) genes, respectively, with hepatitis C virus-related oral lichen planus and disease severity.
|
30290294 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
|
29753376 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We employed three virus derivatives-wild-type Jc1, interferon (IFN)-resistant virus IR, and high-replicative-fitness virus P100-in order to explore additional IFN-α-related virus inhibition mechanisms. pDCs inhibited HCV infectivity and replication and produced IFN-α.
|
30232187 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM.
|
29901821 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peg-IFN/ribavirin was effective and tolerable for thalassemic HCV patients.
|
29097076 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, EVs from patients with hepatitis C exhibited long-lasting antiviral activities during IFN therapy as well.
|
29706960 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We undertook a longitudinal prospective study of 33 individuals with chronic HCV treated with combination pegylated IFN-α, ribavirin, and telaprevir/boceprevir.
|
29263212 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ten patients with HCV (genotype 1) were vaccinated with monocyte-derived DCs, generated in the presence of IFN-α (IFN-DCs) and pulsed with recombinant HCV Core and NS3 proteins.
|
29164490 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV-infected subjects receiving OST did not experience similar PRO improvements with IFN-containing therapy, suggesting that IFN-based therapy may be less suitable for this vulnerable population.
|
29293991 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This prospective, randomized, multicenter study indicated that FLV had no add-on effect when given with SMV/Peg-IFN/RBV combination therapy for genotype 1b HCV-infected patients.
|
28722780 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to correlate the effects of host cytokine single nucleotide polymorphisms of TNF-α (-308 A/G) and IFN-γ (+874 A/T) in spontaneous or IFN induced treatment response in the HCV infected thalassemic individuals.
|
29196132 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, little information is available about the effect of alcohol on interferon-lambda (IFN-λ, type III IFN), a novel candidate for development of therapy for HCV infection.
|
29446489 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
|
30383478 |
2018 |